Puma Biotechnology Inc
Suletud
SektorTervishoid
7.23 -2.3
Ülevaade
Aktsiahinna muutus
24h
Min
7
Max
7.48
Sissetulek | 3M 12M |
|---|---|
Müük | 21M 76M |
P/E Sektori keskmine | 12.344 49.8 |
Kasumimarginaal | 15.633 |
Töötajad | 179 |
EBITDA | 13M 27M |
Soovitused | Neutraalne |
|---|---|
12 kuu keskmine prognoos | -32.89% downside |
Turukapital | 25M 383M |
|---|---|
Eelmine avamishind | 9.53 |
Eelmine sulgemishind | 7.23 |
Tehniline skoor
By Trading Central
Kindlus
Weak Bullish Evidence
Puma Biotechnology Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Puma Biotechnology Inc Prognoos
Hinnasiht
By TipRanks
-32.89% langus
12 kuu keskmine prognoos
Keskmine 5 USD -32.89%
Kõrge 5 USD
Madal 5 USD
Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
